Contact David Ludvigson
Title President & CEO


The Nanomix eLab is a hand-held diagnostic platform that offers fast results, low cost and portability while providing accurate, quantitative results comparable in quality to that provided by central lab testing. Testing is fully automated and intuitive, enabling eLab use at all skill levels, with answers obtained in approximately 10 minutes. Bluetooth connectivity can be used to send data results when test is completed. The system can be used in the hospital or in pre-hospital, remote, or alternative settings. The result is faster decision-making and clinical intervention, and in some cases, the ability to administer treatment in place with lower health care cost.

The initial assay, currently in clinical trials, provides information in approximately 10 minutes for use in initial diagnosis of sepsis. The panel provides rapid, quantitative measurement of 3 sepsis-related biomarkers (lactate, PCT and CRP); data that is not currently available in the clinical decision making time frame and not available at the POC. Future assays will expand Emergency Medicine applications such as cardiac, brain injury, and kidney injury.

Company News

Nanomix Awarded BARDA Contract for Development of Rapid, Mobile, Point-of-Care Assays to Detect COVID-19 Infection

DateApr 8, 2020
Nanomix, a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that the company has been awarded up to approximately $570,000 in funding from Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. These funds support development and testing of COVID-19 point-of-care tests that will run on the Nanomix eLab analyzer, which provides results in less than 15 minutes.
Read More →